Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals positive financial performance with growth in key segments and improved margins. Despite some declines, overall growth in revenue and EPS exceeded expectations. The Q&A section highlights management's confidence in product launches and strategic investments, though some details were vague. The raised guidance and strong pipeline, particularly in cardiovascular and neuroscience, indicate positive sentiment. The combination of these factors suggests a positive stock price movement over the next two weeks.
Key Financial Performance
Revenue Second quarter revenue of $9 billion grew 6.6% reported and 5.5% organic year-over-year. The growth was driven by double-digit growth in Japan and mid-single-digit growth in the U.S., Western Europe, and China. The growth acceleration was attributed to strong performance in the Cardiovascular portfolio, Neuroscience portfolio, and Diabetes business.
Cardiovascular Portfolio Revenue Grew 9%, marking the strongest growth in over a decade (excluding post-pandemic comparisons). The growth was driven by a 71% increase in cardiac ablation solutions (CAS) revenue, with PFA now accounting for 75% of cardiac ablation revenue. This growth offset a 40% decline in cryo revenue.
Neuroscience Portfolio Revenue Grew 4%, with Cranial & Spinal Technologies growing 5% and Core Spine growing 8%. Specialty Therapies had flat results, but improvements are expected in the next quarter. Neuromodulation grew 7%, driven by high single-digit growth in Pain Stim and Brain Modulation.
MedSurg Portfolio Revenue Grew 1%, with Surgical business also growing 1%. Endoscopy business grew 8%, driven by double-digit growth in esophageal products and GI Genius.
Diabetes Business Revenue Grew high single digits, with international markets growing 11%. U.S. growth was lower due to a decline in new orders as customers anticipated the launch of new sensors. However, pent-up demand is materializing with over 35,000 U.S. customer orders for new sensors.
Adjusted Gross Margin 65.9%, up 70 basis points year-over-year. The improvement was driven by pricing (30 basis points), COGS efficiency programs (40 basis points), and offset by business mix and tariffs.
Adjusted Operating Profit $2.2 billion, an increase of 6% year-over-year. Adjusted operating margin was 24.1%, down 20 basis points year-over-year but up 50 basis points sequentially.
Adjusted EPS $1.36, an increase of 8% year-over-year and $0.05 above the midpoint of guidance. The increase was attributed to reduced tax expense and operational improvements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PFA franchise for Afib: Generated significant momentum with 71% growth, driven by Affera mapping system and Sphere-9 catheter. U.S. and international markets grew over 300%. Plans to double revenue soon, adding $1 billion to FY '25 base.
Symplicity for hypertension: Received final Medicare NCD, enabling broad access. Addressable market of 18 million in the U.S. with uncontrolled hypertension. Revenue expected to pick up in the back half of the fiscal year.
Altaviva for incontinence: Positive early signs in U.S. launch. High demand for physician training and consumer interest. Expected to add meaningful growth to public health business.
Diabetes business (MiniMed): High single-digit growth, driven by new sensors Simplera Sync and Instinct. Over 35,000 U.S. customer orders and 9,000 new HCP prescribers. Strong innovation cycle with expanded indications and new product launches.
EP ablation space: Market size over $12 billion, growing mid-20s. Medtronic has low double-digit share with significant runway for growth.
Hypertension market: Addressable market of 18 million people in the U.S. with uncontrolled hypertension. Symplicity procedure expected to drive growth.
Incontinence market: 16 million people in the U.S. affected. Altaviva expected to capture significant share.
Manufacturing scaling: Scaled manufacturing to support growth in PFA franchise and other products.
Increased OpEx investments: Investments made to support revenue growth momentum, particularly in PFA and Symplicity launches.
Gross margin improvement: Adjusted gross margin increased by 70 basis points year-over-year, driven by pricing and COGS efficiency programs.
Tuck-in M&A and portfolio management: Focused on pursuing tuck-in M&A and executing strategic portfolio management to drive growth.
Separation of MiniMed: Planned separation of MiniMed (Diabetes business) on track, expected to complete by end of calendar year '26.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The company faces potential challenges in navigating regulatory approvals and reimbursement pathways, particularly for new products like Symplicity for hypertension and Altaviva for incontinence. While progress has been made, such as receiving Medicare NCD for Symplicity, the process of gaining broader commercial payer coverage and FDA approvals for pipeline products remains a hurdle.
Manufacturing and Supply Chain Risks: Scaling manufacturing to meet high demand for products like Affera mapping systems and new diabetes sensors (Simplera Sync and Instinct) poses risks. Any delays or inefficiencies in ramping up production could impact revenue growth and customer satisfaction.
Product Launch and Market Adoption Risks: The success of new product launches, such as Altaviva and Symplicity, depends on effective physician training, market development, and consumer awareness. Any missteps in these areas could slow adoption and revenue growth.
Competitive Pressures: The company operates in highly competitive markets, such as cardiac ablation and diabetes management. Competitors' advancements or pricing strategies could erode Medtronic's market share and margins.
Economic and Geopolitical Uncertainties: Economic conditions, including inflation and tariffs, as well as geopolitical factors like volume-based procurement in China, could negatively impact costs, pricing, and overall financial performance.
Business Mix and Margin Pressures: The mix of lower-margin products, such as capital equipment in cardiac ablation and early-stage diabetes products, is currently a headwind to gross margins. This could persist until these businesses scale and achieve better economies of scale.
Strategic Execution Risks: The company is pursuing a complex strategy involving pipeline advancements, tuck-in M&A, and portfolio management. Any misalignment or delays in these initiatives could hinder growth and strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Medtronic raised its full-year revenue growth guidance to approximately 5.5%, reflecting confidence in accelerating growth in the back half of the fiscal year. Q3 is also expected to grow at approximately 5.5%, with Q4 showing even stronger growth.
Enterprise Growth Drivers: The company is focusing on key growth drivers such as the PFA franchise for Afib, Symplicity for hypertension, Hugo and soft tissue robotics, and Altaviva for incontinence. These are expected to power revenue growth in the coming quarters and years.
Cardiac Ablation Business: The PFA franchise grew 71% in Q2 and is expected to continue accelerating, with higher CAS growth anticipated in Q3. The company aims to double the revenue of this business soon, adding an incremental $1 billion to the FY '25 base.
Symplicity for Hypertension: Symplicity represents a multibillion-dollar opportunity with an addressable market of 18 million people in the U.S. with uncontrolled hypertension. Revenue is expected to pick up in the back half of the fiscal year and ramp over the next few quarters.
Altaviva for Incontinence: Early signs from the U.S. launch are positive, with oversubscribed physician training programs and strong consumer interest. Altaviva is expected to contribute meaningful growth to Medtronic's public health business over the long term.
Diabetes Business: The launch of new sensors like Simplera Sync and Instinct is expected to accelerate U.S. growth in the back half of the fiscal year. The company has accumulated significant preorders, indicating strong demand.
Hugo Robotics System: The FDA is expected to approve Hugo with a urology indication in the back half of the fiscal year, marking the start of its U.S. market entry. The company is also expanding indications for the system.
Adjusted EPS Guidance: Medtronic increased its fiscal '26 EPS guidance to a range of $5.62 to $5.66, reflecting confidence in its financial performance.
Long-Term Financial Outlook: The company expects high single-digit EPS growth in fiscal year '27, driven by accelerating revenue growth, improved gross margins, and SG&A leverage.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are commercial payers responding to the introduction of Symplicity, and are there any restrictions?
A:Commercial payers are coming online faster than anticipated, driven by patient demand. The Medicare NCD is broad and better than expected, incorporating physician and patient discretion. However, commercial payers emphasize being on a few medications for a while before moving to Symplicity.
Q:What is the implied second-half guidance, and what are the expectations for RDN and the base business?
A:The implied second-half guidance is around 6%. Growth is expected from pipeline products like PFA, Symplicity, Altaviva, and Hugo, as well as a rebound in MedSurg and strong performance in the base business. Margins are expected to improve in the second half due to SG&A leverage and R&D investments.
Q:What is the status of Affera and tibial products, and their potential market impact?
A:Affera's supply and mapper hiring are on track, with strong growth momentum. Tibial has significant market potential, offering faster therapy compared to sacral nerve and BOTOX, and is expected to be incremental to the sacral business, making pelvic health a growth driver.
Q:How is Medtronic planning to balance increased R&D and SG&A investments with operating margin growth?
A:Medtronic is focusing R&D investments on growth drivers like CAS, Ardian, Altaviva, and Hugo, while maintaining innovation in key franchises. SG&A leverage is expected in the second half, with gross margin improvements from cost reductions and pricing stability. Operating margin growth is targeted for 2027.
Q:What is the outlook for tuck-in M&A and venture investments?
A:Medtronic is focused on tuck-in M&A in high-growth segments like Cardiology and Neuroscience, preferring companies close to market. The ventures arm is active, with over 50 investments aimed at feeding the pipeline for future M&A.
Q:What is the expected ramp for Ardian, and how does the NCD impact it?
A:The NCD is seen as an improvement, reducing restrictions and time delays for treatment. The market is as large as anticipated, and Medtronic expects faster adoption, aiming for $400 million U.S. sales by fiscal 2028, with the current run rate around $50 million.
Q:What is the growth algorithm for Medtronic, and how does portfolio management fit in?
A:Medtronic aims for growth acceleration, with contributions from CAS, Ardian, Altaviva, and the base business. Portfolio management remains a focus, ensuring synergies and support for growth drivers. The Diabetes deal is on track, and further portfolio adjustments are being considered.
Q:How is Medtronic positioned for AF ablations in ASCs and TAVR market dynamics?
A:Medtronic sees ASCs as a market expansion opportunity for AF ablations, with dedicated resources and strategies in place. In TAVR, global growth was high single digits in Q2, with expected deceleration in Q3 and a rebound in Q4.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact segments targeted for tuck-in M&A, the precise timeline for achieving SG&A reductions, and the exact financial impact of tariffs and foreign exchange on future margins. Additionally, while optimistic about Ardian's ramp, they did not provide a detailed breakdown of the adoption speed or specific strategies to address isolated systolic hypertension.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Altaviva
COGS efficiency
Diabetes
FDA
Hugo
MiniMed
NCD
Neurovascular
PFA franchise
RD
SGA
Simplera
Symplicity
acceleration CAS
base
basis point
business
capital
demand
device
end market
enterprise driver
hypertension
improvement
increase
investment
launch
line
mapping system
margin
midpoint
mix
momentum
month
opportunity
order
procedure
robotics
sensor
study
tariff
MDT Transcript
Medtronic plc (MDT) Q4 2026 Earnings Call Transcript
Unknown6-3
The earnings call summary lacks detailed information on key aspects such as operational updates, strategic initiatives, and risks, which limits the analysis. The financial section provides only a limited view of revenue comparisons. Without additional insights from the Q&A, the sentiment remains neutral. This lack of comprehensive data suggests no significant short-term stock price movement, resulting in a neutral prediction.
Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Medtronic plc (MDT) Q3 2026 Earnings Call Transcript
Positive2-17
Medtronic's earnings call reveals strong revenue growth, positive product developments, and optimistic guidance. The increase in full-year revenue growth guidance to 5.5% and the raised EPS guidance reflect confidence in future performance. The Q&A section supports this with plans for accelerated growth in key areas and high single-digit EPS growth. Despite some management vagueness, the overall sentiment is positive, with strong growth in the MedSurg and Diabetes businesses and strategic investments. The lack of market cap information limits the prediction accuracy, but the strong fundamentals suggest a positive stock price movement.
MDT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
